FDA Brief

Warning letters Drugs

FDA warning letter to

Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

High riskIssued Aug 6Posted Aug 18Center for Drug Evaluation and Research (CDER)

Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

What happened

FDA reviewed records the company submitted after a July 7, 2025 request under section 704(a)(4) and reviewed its drug listing submissions; this was not an inspection. FDA found current good manufacturing practice (CGMP) deviations for active pharmaceutical ingredients (APIs), including missing process validation, incomplete batch records, unvalidated test methods, and no routine stability testing. FDA also found demecarium bromide and chlorambucil were not listed under the firm's own labeler code, and placed all drugs offered for import from the firm on Import Alert 66-40 on July 21, 2026.

What FDA found

  1. FDA said the firm shipped APIs to U.S. pharmacies that make customized medicines under section 503A without adequate process validation, while telling FDA they were still in development.

    FD&C Act section 501(a)(2)(B)
  2. Batch records lacked critical processing information and major equipment, and FDA said a requested batch record was not provided.

    FD&C Act section 501(a)(2)(B)
  3. The firm did not validate or verify analytical test methods used for drugs sent to the U.S.

    FD&C Act section 501(a)(2)(B)
  4. The firm did not run routine stability testing to support API expiry dates or storage conditions.

    FD&C Act section 501(a)(2)(B)
  5. The firm did not list demecarium bromide and chlorambucil under its own labeler code even though it made and shipped them to the U.S.

    FD&C Act section 510(j); 21 CFR 207.41

What FDA wants

FDA tells the firm to respond in writing within 15 business days to CDER, addressing the CGMP and drug listing deviations and providing the requested assessments, records, and corrective plans. The response must cite FEI 3012560989 and ATTN: Marva Taylor.

Who should pay attention

  • 503A compounding pharmacies that received these APIs
  • companies that buy or repackage APIs from this firm
  • quality teams tracking supplier CGMP and drug listing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk